Design Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
DSGN$10.65-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(11,105) | $(19,294) |
| Reconciliation of net loss to net cash used in operating activities: | ||
| Depreciation | 143 | 129 |
| Stock-based compensation | 3,184 | 3,426 |
| Amortization of premiums on investment securities, net | (1,731) | (1,142) |
| Non-cash lease expense | 4 | 10 |
| Change in operating assets and liabilities: | ||
| Prepaid expense and other assets | (411) | 1,192 |
| Accounts payable and other liabilities | (2,523) | (1,745) |
| Net cash used in operating activities | (12,439) | (17,424) |
| Cash flows from investing activities | ||
| Purchases of investment securities | (45,659) | (33,615) |
| Proceeds from maturities of investment securities | 66,470 | 53,435 |
| Purchases of property and equipment | (195) | (87) |
| Net cash provided by investing activities | 20,616 | 19,733 |
| Cash flows from financing activities | ||
| Proceeds from the exercise of stock options | 20 | — |
| Net cash provided by financing activities | 20 | — |
| Net increase (decrease) in cash and cash equivalents | 8,197 | 2,309 |
| Cash and cash equivalents at beginning of period | 21,200 | 26,500 |
| Cash and cash equivalents at end of period | $29,397 | $28,809 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.